Definitions from Master Collaboration Agreement Sample Clauses

Definitions from Master Collaboration Agreement. Capitalized terms used herein but not defined, including each of the following terms, have the meaning described in the Master Collaboration Agreement: Antibody Accounting Principles Affiliate Antitrust Law Background IP Bankruptcy Code Business Combination Business Day Calendar Quarter Calendar Year Celgene Indemnitees Celgene Independent Products Celgene IP Celgene Option Exercise Notice Celgene Patents Claims Clinical Trial Co-Development & Co-Commercialization Agreement Collaboration Candidate Collaboration IP Commercialization Commercially Reasonable Efforts Confidential Information Control, Controls or Controlled Cover, Covering or Covered Damages CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Data Package Development Development Candidate Diagnostic Product Dollars or $ EMA Equity Purchase Agreement Executive Officers FDA Field Good Clinical Practices or GCP Good Laboratory Practices or GLP Good Manufacturing Practices or GMP Guiding Principles IIT or Investigator Initiated Trial IND Implementation Date Inventions Joint Collaboration IP Jounce Indemnitees Jounce IP Jounce Patents Jounce Program Jounce Program Assets Know-How Law or Laws Licensed Product Litigation Conditions MAA Manufacture or Manufacturing New Drug Application or NDA Option Option Exercise Notice Patents PD-1 Program Person Phase 3 Clinical Trial Pivotal Clinical Trial Product Liability Products Program Prosecution and Maintenance Regulatory Approval Regulatory Authority Regulatory Materials CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Reimbursable Costs Resulting Patents Specifically Directed Sublicensee Target Territory Third Party Third Party License United States or U.S. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT T...